Premium
Proof of Concept for the Inhibition of Foot‐and‐Mouth Disease Virus Replication by the Anti‐Viral Drug 2′‐ C ‐Methylcytidine in Severe Combined Immunodeficient Mice
Author(s) -
Lefebvre D. J.,
De Vleeschauwer A. R.,
Goris N.,
Kollanur D.,
Billiet A.,
Murao L.,
Neyts J.,
De Clercq K.
Publication year - 2014
Publication title -
transboundary and emerging diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.392
H-Index - 63
eISSN - 1865-1682
pISSN - 1865-1674
DOI - 10.1111/tbed.12069
Subject(s) - virology , foot and mouth disease , virus , vaccination , viral replication , disease , medicine , antiviral drug , immunology , biology
Summary Recent European contingency plans envisage emergency vaccination as an animal‐friendly control strategy for foot‐and‐mouth disease ( FMD ). Anti‐viral drugs may be used as an alternative or complementary measure. We here demonstrate that the nucleoside analogue 2′‐ C ‐methylcytidine (2′ CMC ) protects severe combined immunodeficient ( SCID ) mice against lethal FMD virus infection. In brief, SCID mice were inoculated with serotype A FMD virus and treated for five consecutive days with 2′ CMC . All 15 treated mice remained healthy until the end of the study at 14 days post‐infection (dpi). At that time, viral RNA was no longer detected in 13 of 15 treated mice. All eight untreated mice suffered from an acute generalized disease and were euthanized for ethical reasons on average at 4 dpi. These results illustrate the potential of small molecules to control FMD .